BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 9657734)

  • 1. Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia.
    Imaizumi M; Suzuki H; Yoshinari M; Sato A; Saito T; Sugawara A; Tsuchiya S; Hatae Y; Fujimoto T; Kakizuka A; Konno T; Iinuma K
    Blood; 1998 Jul; 92(2):374-82. PubMed ID: 9657734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
    Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G
    Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel mutation in the PML/RARalpha chimeric gene exhibits dramatically decreased ligand-binding activity and confers acquired resistance to retinoic acid in acute promyelocytic leukemia.
    Takayama N; Kizaki M; Hida T; Kinjo K; Ikeda Y
    Exp Hematol; 2001 Jul; 29(7):864-72. PubMed ID: 11438209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARalpha fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy.
    Ding W; Li YP; Nobile LM; Grills G; Carrera I; Paietta E; Tallman MS; Wiernik PH; Gallagher RE
    Blood; 1998 Aug; 92(4):1172-83. PubMed ID: 9694705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of PML/RARalpha is lethal to retinoic acid-resistant promyelocytic leukemia cells.
    Nason-Burchenal K; Allopenna J; Bègue A; Stéhelin D; Dmitrovsky E; Martin P
    Blood; 1998 Sep; 92(5):1758-67. PubMed ID: 9716606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells.
    Côté S; Rosenauer A; Bianchini A; Seiter K; Vandewiele J; Nervi C; Miller WH
    Blood; 2002 Oct; 100(7):2586-96. PubMed ID: 12239173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia.
    Guidez F; Ivins S; Zhu J; Söderström M; Waxman S; Zelent A
    Blood; 1998 Apr; 91(8):2634-42. PubMed ID: 9531570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered nuclear cofactor switching in retinoic-resistant variants of the PML-RARα oncoprotein of acute promyelocytic leukemia.
    Farris M; Lague A; Manuelyan Z; Statnekov J; Francklyn C
    Proteins; 2012 Apr; 80(4):1095-109. PubMed ID: 22228505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapse of acute promyelocytic leukemia with PML-RARalpha mutant subclones independent of proximate all-trans retinoic acid selection pressure.
    Gallagher RE; Schachter-Tokarz EL; Zhou DC; Ding W; Kim SH; Sankoorikal BJ; Bi W; Livak KJ; Slack JL; Willman CL
    Leukemia; 2006 Apr; 20(4):556-62. PubMed ID: 16437139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcription therapy for acute promyelocytic leukaemia.
    Douer D
    Expert Opin Investig Drugs; 2000 Feb; 9(2):329-46. PubMed ID: 11060680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variant-type PML-RAR(alpha) fusion transcript in acute promyelocytic leukemia: use of a cryptic coding sequence from intron 2 of the RAR(alpha) gene and identification of a new clinical subtype resistant to retinoic acid therapy.
    Gu BW; Xiong H; Zhou Y; Chen B; Wang L; Dong S; Yu ZY; Lu LF; Zhong M; Yin HF; Zhu GF; Huang W; Ren SX; Gallagher RE; Waxman S; Chen GQ; Wang ZG; Chen Z; Fu G; Chen SJ
    Proc Natl Acad Sci U S A; 2002 May; 99(11):7640-5. PubMed ID: 12032336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered ligand binding and transcriptional regulation by mutations in the PML/RARalpha ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia.
    Côté S; Zhou D; Bianchini A; Nervi C; Gallagher RE; Miller WH
    Blood; 2000 Nov; 96(9):3200-8. PubMed ID: 11050004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation.
    Shao W; Benedetti L; Lamph WW; Nervi C; Miller WH
    Blood; 1997 Jun; 89(12):4282-9. PubMed ID: 9192750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute promyelocytic leukemia: a novel PML/RARalpha fusion that generates a frameshift in the RARalpha transcript and ATRA resistance.
    Zayed A; Couban S; Hayne O; Sparavalo N; Shawwa A; Sadek I; Greer W
    Leuk Lymphoma; 2007 Mar; 48(3):489-96. PubMed ID: 17454588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganization.
    Nason-Burchenal K; Maerz W; Albanell J; Allopenna J; Martin P; Moore MA; Dmitrovsky E
    Differentiation; 1997 Aug; 61(5):321-31. PubMed ID: 9342843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alteration in the cellular response to retinoic acid of a human acute promyelocytic leukemia cell line, UF-1, carrying a patient-derived mutant PML-RARalpha chimeric gene.
    Sato A; Imaizumi M; Hoshi Y; Rikiishi T; Fujii K; Kizaki M; Kagechika H; Kakizuka A; Hayashi Y; Iinuma K
    Leuk Res; 2004 Sep; 28(9):959-67. PubMed ID: 15234573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TBLR1 fuses to retinoid acid receptor α in a variant t(3;17)(q26;q21) translocation of acute promyelocytic leukemia.
    Chen Y; Li S; Zhou C; Li C; Ru K; Rao Q; Xing H; Tian Z; Tang K; Mi Y; Wang B; Wang M; Wang J
    Blood; 2014 Aug; 124(6):936-45. PubMed ID: 24782508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant AF-2 domain of PML-RARalpha in retinoic acid-resistant NB4 cells: differentiation induced by RA is triggered directly through PML-RARalpha and its down-regulation in acute promyelocytic leukemia.
    Kitamura K; Kiyoi H; Yoshida H; Saito H; Ohno R; Naoe T
    Leukemia; 1997 Nov; 11(11):1950-6. PubMed ID: 9369431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo.
    Zhou DC; Kim SH; Ding W; Schultz C; Warrell RP; Gallagher RE
    Blood; 2002 Feb; 99(4):1356-63. PubMed ID: 11830487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The molecular biology of acute promyelocytic leukemia.
    Slack JL; Gallagher RE
    Cancer Treat Res; 1999; 99():75-124. PubMed ID: 9891864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.